Auriga
Auriga USA is a research and trading platform that focuses on growth sectors within the Health Care and Technology verticals. We operate out of our main office in New York City, and also have satellite offices in Boston, San Francisco, Philadelphia, San Diego, and Washington D.C. This regional network helps us to keep abreast of key corporate developments, enhance client relationships, and provide more efficient product distribution to meet clients' investment needs. The firm is committed to providing our clients with critical information flow, investment ideas, and access to industry experts.
View Older Stories View More Recent Stories
-
Auriga Reiterates a 'Buy' on Steven Madden (SHOO); Positive Take-aways From CEO Meeting
-
Auriga Maintains a 'Buy' on DSW Inc. (DSW); Guidance and Dividend Raised on Strong Q1
-
Streetinsider.com's Hot Lunchtime Reads 05/18: (FB) (MA) (SQNM) (CVH) (JPM)
-
Auriga Securities on Sequenom (SQNM): Coventry (CVH) Giveth, Coventry Taketh Away
-
Auriga Reiterates a 'Buy' on Quality Systems (QSII); Q4 Meets Reduced Expectations; Accumulate on Weakness
-
Auriga Reiterates a 'Buy' on Aruba Networks (ARUN); Strength of Underlying Fundamentals
-
Auriga Maintains a 'Hold' on Schnitzer Steel (SCHN); Cutting Estimates on Lowered Outlook
-
Auriga Reiterates a 'Buy' on Spectrum Pharmaceuticals (SPPI); Generic Leucovorin Shortage Continues
-
Auriga Reiterates a 'Buy' on Ubiquiti Networks (UBNT); Trends Remain Robust
-
Auriga Reiterates a 'Buy' on Herbalife (HLF); Shares Still Offer Material Upside
-
Auriga Maintains a 'Buy' on Patterson Companies (PDCO); Q4 Preview
-
Auriga on Solar Power/CleanTech: Solar Photovoltaics: US - China Solar Trade Investigation; Upcoming Catalysts
-
Auriga Upgrades Quality Systems (QSII) to Buy; Pre-Announcement Presents Opportunity
-
Auriga Maintains a 'Buy' on Globe Specialty Metals (GSM); In-line Results; Pricing Still An Issue
-
Auriga Reiterates a 'Buy' on Impax Laboratories (IPXL); Positive After Meetin with Management
-
Auriga Reiterates a 'Buy' on DSW Inc. (DSW); Channel Checks Solid
-
UPDATE: Auriga Downgrades Dole (DOLE) to Hold; Valuation Call
-
Auriga on Canadian Solar (CSIQ); Traction on Shipments, Costs, EPC Visibility Offset by Sharp ASP Erosion
-
Auriga Maintains a 'Hold' on Heartware Int'l (HTWR); Impressive Growth in Europe
-
Compass Point Reiterates a 'Buy' on Howard Hughes Corp (HHC); Raising PT After Solid Quarter
-
Auriga Reiterates a 'Buy' on Medicis (MRX); Q1 Beat Underscores Execution
-
Auriga Reiterates a 'Buy' on Protalix BioTherapeutics (PLX); Eyes on Elelyso launch in U.S.
-
Auriga Maintains a 'Buy' on MEMC Electronic Materials (WFR); Valuation the Real Issue
-
Streetinsider.com's Hot Lunchtime Reads 05/09: (S) (kkd) (WEN) (GLD) (TPX) (HLF)
-
Auriga Maintains a 'Hold' on ADTRAN (ADTN); NSN Deal Closes
-
Auriga Reiterates a 'Buy' on CPI Aerostructures (CVU); Transformational Bids in the Pipeline
-
Auriga Maintains 'Buy' on Herbalife (HLF); Takeaways From Analyst Meeting
-
Auriga Reiterates a 'Buy' on Medifast (MED); Still Like Long-Term, But Cutting Estimates on Mixed Results
-
Auriga Downgrades Chiquita (CQB) to Hold; Cutting Estimates on Tough Conditions
-
Auriga Maintains a 'Buy' on Perrigo Co. (PRGO); Accumulate Shares on Weakness
-
Auriga Maintains a 'Hold' on Henry Schein (HSIC); Solid Q1, But Lack of Visibility Keeps Us Sidelined
-
Auriga Maintains a 'Hold' on Heartware Int'l (HTWR); Enrollment Completed for ENDURANCE Trial
-
Auriga Reiterates a 'Buy' on Jazz Pharmaceuticals (JAZZ); Lifting Numbers on 'Beat & Raise'
-
Auriga Reiterates a 'Buy' on DepoMed (DEPO); Q1 Beats...Taking Proactive Approach
-
Auriga on Healthcare Services: MAKO Misses 1Q12 Expectations; Read-through for HMA
-
Auriga Reiterates a 'Hold' on Salix Pharmaceuticals (SLXP); Q1 Tops Estimates, But Upside Priced In
-
Auriga Maintains a 'Buy' on Affymax, Inc. (AFFY); Milestone Payments Drive Q1 Upside; Continue Seeing Market Opp for Omontys
-
Auriga Reiterates a 'Buy' on Broadsoft (BSFT); Solid Q1 Overshadowed by Guidance
-
Streetinsider.com's Hot Lunchtime Reads 05/07: (SPWR) (MU) (GRPN) (LVS) (AAPL) (CSCO)
-
Auriga Maintains a 'Buy' on SunPower (SPWR); Q1 On Track; Possible Upside to FY12
-
Auriga Reiterates a 'Buy' on Haynes International (HAYN); Impressive Improvement in Gross Margins
-
Auriga Upgrades Protalix BioTherapeutics (PLX) to Buy
-
Auriga Upgrades Weight Watchers (WTW) to Buy
-
Auriga Maintains a 'Buy' on Ubiquiti Networks (UBNT); Operating Expenses Rising, But Now 'Lawyered Up'
-
Auriga Reiterates a 'Buy' on Omnicell (OMCL); In-line Earnings and MTS Acquisition
-
Auriga Reiterates a 'Buy' on MedAssets (MDAS); See 30% Upside in Next 12-Months
-
Auriga Maintains a 'Hold' on Weight Watchers (WTW); First Look At Disappointing Q1
-
Auriga Reiterates a 'Hold' on Boston Beer Company (SAM); Raising Numbers, But Performance Priced In
-
Streetinsider.com's Hot Lunchtime Reads 05/03: (BID) (BAC) (AMT) (GMCR) (BBBY) (AAPL)
-
Auriga Maintains a 'Buy' on Steven Madden (SHOO); Reports Inline Q1; Increases Full Year Guidance

